Catalog |
name |
Description |
price |
R-M-5099 |
Biotinyl-CBP501 Affinity Peptide,cas:2022956-39-2 |
An affinity selection of T7 phage-displayed peptide using biotinylated CBP51, which identified this 14-mer peptide. It showed similarity to a portion of the alphaC helix of human 14-3-3e, suggesting that CBP51 may bind to this region. |
price> |
R-M1-8825 |
Fmoc-L-Cys(S-DMP)-OH |
Fmoc-L-Cys(S-DMP)-OH is a protected form of cysteine suitable for solid-phase peptide synthesis that enables the introduction of cysteine residues into peptide sequences for subsequent modifications or disulfide bonding. |
price> |
R-M1-8222 |
MATGNAD(heptapeptide) |
MATGNAD(heptapeptide) consisting of seven amino acids linked by peptide bond. |
price> |
R-M1-8223 |
MATGNA (Hexapeptide) |
MATGNA (Hexapeptide) consisting of six amino acids linked by peptide bond. |
price> |
R-M1-8277 |
FMOC-Lys(5/6-FAM)-OH |
FMOC-Lys(5/6-FAM)-OH is a building block for in-sequence Lys labeling by FAM. FAM is one of the most common donor dyes for preparing FRET peptides (often paired with TAMRA or TQ2). |
price> |
R-M1-8352 |
ANG(TFFYGGSRGKRNNFKTEEYC) |
ANG (TFFYGGSRGKRNNFKTEEYC) is a peptide provided by ruixibio. |
price> |
R-M1-8362 |
STKKLSECLKRIGDELDSNM-GG-rrrrrrrrr(lowercase:D-type) |
STKKLSECLKRIGDELDSNM-GG-rrrrrrrrr is a synthetic peptide that can modify nanomaterials, phospholipids, and more. |
price> |
R-M1-8363 |
D-type(rrrrrrrrr) |
D-type(rrrrrrrrr) is a synthetic peptide that can modify nanomaterials, phospholipids, and more. |
price> |
R-M1-8450 |
WHRSYYTWNLNT |
WHRSYYTWNLNT is a sequence peptide that can be customized with various peptide modified compounds. |
price> |
R-M1-8463 |
PLGVRGC |
Peptide:PLGVRGC is a peptide sequence ,the PLGVRGC sequence is known as the PTHrP(1-7) peptide, and is thought to have biological activity similar to that of the full-length PTHrP protein. This peptide sequence has been shown to stimulate osteoblast (bone-forming cell) proliferation and differentiation, enhance bone mineralization, and decrease bone resorption in vitro and in vivo.
The PLGVRGC peptide has also been investigated for its potential therapeutic applications in various bone-related disorders, such as osteoporosis, bone fractures, and bone cancer metastasis. It has been suggested that the peptide may act as an osteoanabolic agent, promoting bone formation and improving bone density. |
price> |